Total Revenue: $1.05 billion, up 20% year-over-year. Product Revenue: $922 million, a 26% increase year-over-year. Jakafi Revenue: $709 million, 24% growth year-over-year. Opzelura Revenue: $119 million, up 38% year-over-year. Niktimvo Revenue: $14 million from initial launch. Cash Position: $2.4 billion at the end of the quarter. R&D Expenses: $437 million, a 2% increase year-over-year. SG&A Expenses: $326 million, an 8% increase year-over-year. Operating Expenses: Increased 6% year-over-year. Jakafi Full-Year Revenue Guidance: Raised to $2.95 billion to $3 billion.

Warning! GuruFocus has detected 3 Warning Sign with INCY.

Release Date: April 29, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Incyte Corp (NASDAQ:INCY) reported a strong financial performance with a 20% increase in total revenues year-over-year, reaching $1.05 billion. The company successfully launched Niktimvo, contributing $14 million in net product revenues in the first quarter. Jakafi's net product revenue grew 24% year-over-year to $709 million, driven by strong demand and increased patient numbers. Opzelura's network revenue increased by 38% compared to the same quarter last year, with significant growth in the US and European markets. Incyte Corp (NASDAQ:INCY) has a robust pipeline with plans for multiple product launches and pivotal trial readouts in 2025, indicating potential for future growth.

Negative Points

The company faces potential risks and uncertainties that could affect future results, as highlighted in their forward-looking statements. Despite strong initial sales, Niktimvo's revenue included a significant portion of inventory build, which may not be sustainable. Opzelura's growth was partially offset by a reduction in channel inventory, impacting net revenue growth. The company anticipates limited gross to net favorability for Jakafi in the remaining quarters of 2025 due to changes in Part D coverage. Incyte Corp (NASDAQ:INCY) continues to face challenges in the competitive landscape, particularly in the development of new treatments for chronic spontaneous urticaria and hidradenitis suppurativa.

Q & A Highlights

Q: Can you discuss the growth drivers for Jakafi, particularly in polycythemia vera (PV), and how the recent Phase 3 data might impact its use? A: Mohamed Issa Issa, Executive Vice President & Head - US Oncology, explained that the growth in PV is driven by both new patient starts and continued use by existing patients. The recent Phase 3 data for a hepcidemimetic in PV is expected to be used in combination with Jakafi, which remains the only FDA-approved JAK inhibitor for PV after HU failures or intolerance.

Story Continues

Q: Where do you see Povorcitinib fitting in the treatment landscape for chronic spontaneous urticaria (CSU)? A: Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer, stated that Povorcitinib could be used both before biologics like XOLAIR and after antihistamines, depending on patient preference. It offers an oral option for managing CSU, potentially addressing both patient populations.

Q: What are the expectations for the CALR compound data release this year? A: Pablo Cagnoni, President, Head of Research and Development, confirmed that substantive data will be presented this year, including dose escalation results, data in essential thrombocythemia (ET) and myelofibrosis, and clinical endpoints, along with early data on allele burden.

Q: Can you provide an update on the Ruxolitinib extended release (XR) program? A: Steven Stein, Executive Vice President, Chief Medical Officer, mentioned that bioequivalence has been achieved, and stability data will be completed by the end of the year. The response to the CRL will be filed by the end of the year, with expected approval by mid-next year.

Q: How is the launch of Niktimvo progressing, and are there any notable dynamics affecting its sales? A: Mohamed Issa Issa noted that Niktimvo's launch is progressing well, with 95% of top accounts using it. The initial sales include some inventory build, but the product is seeing strong uptake due to high patient need and positive feedback from healthcare providers.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments